explore -WSS

explore

author：hotspot 2025-09-03 14:37:08 - browse：97

David Liu and Jonathan Wosen on the STAT Summit stage. — David Liu (left) with reporter Jonathan Wosen at the 2022 STAT Summit. STAT

David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching a company focused on delivering gene-editing machinery to precise cells and tissues in the body, STAT has learned.

The company, known as Nvelop, already raised a $100 million seed round last year, according to PitchBook. It is being run by Jeff Walsh, a former top executive at Bluebird Bio, and it recently recruited Bluebird’s head of research, Melissa Bonner, according to two people with knowledge of the situation. Bluebird had not previously disclosed Bonner’s departure.

Nvelop is the latest entry in a race among top labs and deep-pocketed investors to solve a delivery problem that has stunted efforts to turn CRISPR and other genetic tools into disease-altering medicines. The goal is to develop a cargo system precise enough to deliver CRISPR or other machinery to cells of a researchers’ choosing, particularly tissues that have been hard to reach with previous approaches, like neurons, muscle, and blood stem cells.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： How to make the FDA’s new prescription one

WSS

Former Pear Therapeutics executives start new VC firm

PEPFAR is under serious threat — and so is global health

FDA approves updated Covid vaccines

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Can U.S. cancer drug shortages be fixed?

California store owner shot dead in dispute over displaying Pride flag: Police

leisure time

explore

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Food makers tried to stack nutrition panel with preferred experts

Heart attack and stroke risk calculators need revising

How housing is health care on Long Island

In Memoriam: Notable people who died in 2023

Hospitals consider fixing cancer drug shortages on their own

The cancer drug shortage isn’t new — and neither are the solutions

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Virginia high school admissions case could be legal follow

FDA greenlights medical device to combat bladder issues

focus

White House touts steps to stem shortages of cancer treatments

FDA advisory panel to debate high blood pressure devices

Acelyrin, a rare IPO success, stumbles in its first big test

Listen: Vivek Ramaswamy's star turn & leaky drug data

PEPFAR is under serious threat — and so is global health

What to make of Biden’s latest efforts on cancer research

hotspot

hotspot

focus

focus